Real life experiences in HCV management in 2018

Antonio Craxi, Vito Di Marco, Vincenza Calvaruso, Alessio Aghemo, Pietro Andreone, Valeria Cento, Maurizia Rossana Brunetto, Alfredo Alberti, Carlo Federico Perno, Giovanni Battista Gaeta, Antonio Gasbarrini, Francesca Ceccherini-Silberstein, Giovanni Di Perri, Stefano Bonora, Antonio Gasbarrini, Giovanni Raimondo, Tullio Prestileo, Carlo Federico Perno, Massimo Andreoni, Francesca Ceccherini-SilbersteinMassimo Puoti, Sergio Babudieri, Carlo Federico Perno, Fabio Cartabellotta, Francesca Ceccherini-Silberstein, Piero Colombatto, Sergio Babudieri, Nicola Coppola, Alessia Ciancio, Adriano Pellicelli, Giuliano Rizzardini, Stefano Fagiuoli, Massimo Puoti, Massimo Andreoni, Anna Linda Zignego, Gloria Taliani, Pietro Lampertico, Raffaele Bruno, Savino Bruno, Nicola Caporaso, Mauro Viganò

Risultato della ricerca: Articlepeer review

9 Citazioni (Scopus)


Introduction: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, withapproximately 71 million chronically infected individuals worldwide. Treatment of chronichepatitis C has considerably improved in the last few years thanks to the introduction of directacting antivirals able to achieve sustained virological response in more than 95% of patients.Successful anti-HCV treatment can halt liver disease progression and solve the HCV-related extrahepatic manifestations, eventually reducing liver-related and overall mortality.Areas covered: With the aim to respond to unmet needs in patient’s identification, universal accessto antiviral therapy and treatment optimization in specific setting of HCV-infected patients, a groupof Italian experts met in Stresa in May 2018. The summary of the considerations arising from thismeeting and the final statements are reported in this paper.Expert commentary: All the advances on HCV cure may have a real clinical impact not only inindividual patients but also at the social health level if they are applied to all infected patients,independently from the stage of liver disease. Further improvements are needed in order toattain HCV elimination, such as the development of an enhanced screening program working inparallel to the present treatment options.
Lingua originaleEnglish
pagine (da-a)117-128
Numero di pagine12
RivistaExpert Review of Anti-Infective Therapy
Stato di pubblicazionePublished - 2018

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2400.2404???
  • ???subjectarea.asjc.2700.2726???
  • ???subjectarea.asjc.2400.2406???
  • ???subjectarea.asjc.2700.2725???


Entra nei temi di ricerca di 'Real life experiences in HCV management in 2018'. Insieme formano una fingerprint unica.

Cita questo